London, UK-based Baseimmune, a biotech firm focusing on vaccine development, has raised $11.3 million in a Series A funding round.

The investment in Baseimmune was led by MSD Global Health Innovation Fund and IQ Capital, with further support from Hoxton Ventures, Creator Fund, Beast Ventures, and Maki.vc, all of whom are returning investors.

Baseimmune leverages artificial intelligence to predict pathogen mutations. The company was founded in 2019 by Joshua Blight and Ariane Gomes, alumni of the Jenner Institute at the University of Oxford, along with software engineer Phillip Kemlo.